Why the study?
Is intravenous recombinant hirudin safe and effective for the treatment of acute venous thrombo-embolism?
Is intravenous recombinant hirudin safe and effective for the treatment of acute venous thrombo-embolism?
In a small pilot study, intravenous recombinant hirudin appeared safe and showed potential efficacy in reducing pulmonary vascular obstruction in patients with acute venous thrombo-embolism.
Case report suggests hirudin safety in acute VTE; hypothesis-generating and should not change practice.
Recombinant Hirudin (rH) is an anticoagulant agent with a specific antithrombin activity independent of antithrombin III. We report the results of the first open pilot study on the curative treatment of acute venous thrombo-embolism (VTE) with rH (HBW 023) in ten patients. The dose of rH tested was 0.07 mg/kg (i.v. bolus) followed by 0.05 mg kg-1 h-1 (i.v. infusion) for 5 days, without activated partial thromboplastin time (APTT) adjustment. Within the trial, no death, VTE recurrence or major bleeding was observed; lung scan pulmonary vascular obstruction improved from 44 to 37%, whereas the venographic Marder score was unchanged; APTT ratio ranged between 1.2 and 2.8. The dose of rH assessed in this study seems to be safe and efficient in the treatment of acute VTE.
No takes yet. Share an insight, caveat, or question.
Parent et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: